News Helsinn Group and BridgeBio Pharma Announce Update to Strategic Collaboration to Develop, Manufacture and Commercialize Infigratinib in Oncology Indications in the U.S.
News Helsinn Launches Fully Integrated Targeted Therapy (FITT) Strategy and Announces Leadership and Structural Changes
News Helsinn announces European Commission approval of the liquid formulation of AKYNZEO®(fosnetupitant/palonosetron)
News Helsinn and Fosun Pharma sign exclusive license and distribution agreements for Aloxi®, Akynzeo® oral, NEPA IV and anamorelin in Mainland China, Hong Kong SAR and Macau SAR
News Helsinn announces the Launch of Adlumiz® (anamorelin) for the Treatment of Cancer Cachexia in Japan
News Helsinn publishes PROVe MF-CTCL study providing new data for mechlorethamine gel use in a real-world setting
News ONO Receives a Manufacturing and Marketing Approval of Adlumiz® (Anamorelin), a Ghrelin Receptor Agonist for the Treatment of Cancer Cachexia in Japan
